Differential gene expression of BCL‐2, ZEB2‑AS1 and BALR‐2 in prostate cancer and benign prostatic hyperplasia

Abstract

Prostate cancer (PCa) and benign prostate hyperplasia (BPH) are highly prevalent heterogeneous disorders among men. Whereas PCa and BPH underline common pathological features, apoptotic-related genes might be differentially expressed in these diseases. This study was aimed at testing BCL-2 as well as BALR-2 and ZEB2-AS1 apoptosis-related long non-coding RNA (lncRNA) in patients with PCa and BPH. The expression levels of the BCL-2 gene and ZEB2-AS1 lncRNA were upregulated in tumoural tissues in comparison to adjacent non-cancerous tissues (ANCTs) and BPH tissues. In contrast, the expression level of BALR-2 lncRNA was significantly higher in BPH compared with tumoural tissues. Furthermore, while no association was noticed between the relative expression of ZEB2-AS1 and the tumour grade, the relative expression of BCL-2 and BALR-2 is strongly associated with a higher grade of the tumour in PCa samples compared with the ANCTs. The receiver operating characteristic (ROC) curve analysis indicated the highest specificity and diagnostic value in distinguishing PCa and ANCTs as well as PCa and BPH, respectively. In conclusion, altered expression of BCL-2 and BALR-2 was observed to be associated with tumoural progression and could be used as potential candidates for distinguishing PCa tissues from ANCTs or BPH samples.

Effect of Lactobacillus rhamnosus GG Supplementation on the Growth Performance, Survival rate and Morphometry of Grass Carp (Ctenopharyngodon idella)

“…Long-term BPH can also lead to complications such as infection and stone formation, and may even worsen into prostate cancer, posing a further threat to patients' health. The treatment methodologies for BPH mainly include drug therapy and surgical treatment (Ahani et al, 2022;Huck et al, 2022). Commonly utilized drugs currently include α1-adrenergic receptor blockers, 5α-reductase inhibitors, and β3-adrenergic receptor agonists.…”